UNIQUE CRYO SPRAY

FOR HOLLOW & HUMID ORGANS

 
 

ABOUT US

Vessi Medical is developing an innovative, IP protected cryo spray for hollow & humid organs, a new approach in the treatment of Non Muscle Invasive Bladder Cancer (NMIBC).

 

Vessi’s first indication, low-grade NMIBC is account for around 50% of bladder cancer patients. 

First in human study (FIH) clinical trials initiated 2021.

 

THE NEED

Recurrent disease, that necessitate repeat treatments, with reduced quality of life

Transurethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. A costly, invasive surgical procedure, TURBT is performed in a hospital under general anesthesia, with significant complications. Moreover, in up to 80% of cases the cancer returns, and that results in multiple repeat procedures which further reduce patients’ quality of life. 

Vessi’s initial target is the

$1.2 billion NMIBC market

10

TH

Most common cancer

75%

75% of all bladder cancers

are NMIBC

1.7M

1.7 million suffer globally

from NMIBC

570K

570,000 new cases every year!

NMIBC is defined as a cancer on the surface of the inner lining of the bladder. Physical symptoms often include problems urinating, pain and blood in the urine, or sexual dysfunction; however, it may also affect mental health and lead to a significant decrease in quality of life.

2.png

The standard of care has numerous limitations

bleeding.png

Bleeding (14.1%) and perforations (4.7%) with frequent extraperitoneal extravasation of urine

residual tumor.png

Residual tumors 2cm around visible tumor, in 13% of Ta and in 35% of T1 tumors

recurrances.png

50%-80% Recurrences after TURBT, most during the first year

 

Unique cryo spray for hollow & humid organs

Vessi's minimally invasive solution for NMIBC provides a new therapeutic alternative to surgery. The company's bladder-specific cryotherapy reduces the cost and the complications associated with TURBT.

       Easy to use

       Potentially no anesthesia, office procedure

       Reduces complications

not spreading.png

Not spreading

the tumor

non contact.png

Non-contact

ablation

easily.png

Easily treats

lesion margins

OUR SOLUTION

THE VESSI SYSTEM

The Vessi system consists of a standalone console and a disposable device that is inserted transurethrally into the bladder.

Shot_09_small2.jpg

Vessi's advantages

1.png
2.png
1.png

Visualization in liquids & gases mix environment

4.png
3.png

Visualization inside hollow organs during surface cryotherapy

Flexible Design

potential no anesthesia

office procedure

Balances the ideal cooling temperature & pressure

EASY

TO USE

POTENTIALLY NO ANESTHESIA, OFFICE PROCEDURE

REDUCES COMPLICATIONS

Publications

PATIENT

Vessi Medical Reports 1st in Human, 2021

The procedure demonstrated ease of use, speed of

activation and completion, without complications 

FIH Procedure with Vessi Medical's, 2021

Vessi announced that it successfully completed a first-in-human case with its minimally invasive cryoablation

TEAM

Eyal Kochavi.png

Eyal Kochavi,

Founder & CEO

Seasoned medical device manager with vast cryotherapy experience; prior positions with Motus GI, Galil Medical, Given Imaging; MSc, MBA, Technion Israel institute of Technology

Moti Simchon.png

Moti Simchon,

Cryogenics Expert

Years of experience in pneumatics, fine mechanics, and cryogenics; prior position in the defense industry

koby.png

Koby Luleko,

Project Manager

Engineering leader at ET View, R&D development at Motus GI; experience in medical device V&V process, transfer to production and early stages development

Prof. Gilad E. Amiel.png

Prof. Gilad E. Amiel,

Scientific Advisor

Chairman, Department of Urology, Rambam Health Care Campus, Israel; adjunct Associate Professor of Urology, Baylor College, Houston, Texas; former President of the American Association for Cancer Education (AACE)

Capture-5-e1580640219542_edited.jpg

Dr. Benny Zeevi, MD

Chairman

Venture capitalist deeply involved in the Israeli life sciences over 20 years. A certified Pediatric Cardiologist, was Director of Pediatric Catheterization Unit, Schneider Children's, and Professor and part-time clinical staff at the Children's Hospital, Harvard, Boston

 
 

CONTACT US

Thanks! Message sent.

Blue gradient-01.png

For Information

Vessi Medical
Misgav Industrial Park
Misgav, Israel

 

 

 


Eyal Kochavi, CEO & Founder
Mail: eyal@vessimed.com
Telephone: +972.52.523.5454

  • White LinkedIn Icon